Skip to content
Markets News
Stocks1 min read

Roche Reports 43.1% Proteinuria Reduction in Sefaxersen Trial

Makkler Newsroom
October 23, 2026 · Based on reporting by GlobeNewswire, finanzen.net

Interim phase III results showed a significant reduction at 37 weeks, while the study continues to track kidney function.

Key takeaways

  • Sefaxersen reduced proteinuria by 43.1% versus placebo at 37 weeks.
  • The phase III study will continue to assess kidney function over two years.

Roche said its investigational drug sefaxersen reduced proteinuria by 43.1% versus placebo after 37 weeks in an interim analysis of a phase III trial in people with IgA nephropathy. The reduction was statistically significant, the company said.

Treatment effects were consistent across all prespecified patient subgroups. Roche said the drug’s safety profile matched results from an earlier phase II study, with no new safety signals.

The study will continue to assess kidney function over two years, with results measured at week 105. Sefaxersen is designed as a once-monthly injection under the skin that patients can administer at home.

Topics
ROROG.SWSefaxersen

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.